Up­dat­ed: Akero re­deems its fail­ure in se­vere MASH with longer-term da­ta

Akero Ther­a­peu­tics claimed a win in se­vere MASH on Mon­day morn­ing, as the com­pa­ny’s can­di­date efrux­ifer­min showed a 24% ben­e­fit on …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.